Phone: +385 1 8886300


Welcome to Fidelta

Your partner for drug discovery

Entrust your project to us and gain access to our extensive experience in pharma R&D, our scientific expertise and outstanding capabilities covering the entire drug discovery process - from target validation to early preclinical development. At Fidelta, we are driven to provide high quality drug discovery services and solutions to our clients.

Integrated drug discovery is what we do best

Looking for a single drug discovery provider who can take your project from target to preclinical development?
Fidelta has the necessary set up and expertise for fully integrated drug discovery, backed up by a successful delivery track record.

Our goal is to provide efficacious, safe and differentiated preclinical candidates. We place strong emphasis on translational science, focusing on disease relevant animal models and ex-vivo studies where appropriate from patient samples, with the discovery process driven by expert medicinal chemistry and ADME/PK.
Inflammation and infection are our core expertise, accompanied by experience in additional therapeutic areas.
Macrocyclic chemistry is a particular forte of Fidelta.

Excellence in providing individual services and service packages

Choose from a range of stand-alone services or let us customize a service package to meet your specific needs in drug discovery. Please click on the area of your interest and find out what we can do in:

In addition to our standard list of services and assays we offer customized assay development and validation, both in vitro and in vivo, upon request.

Building long term relationships is important

Strong believers in building long-term relationships with our clients, we pride ourselves in working according to the highest scientific quality standards through close communication with our clients, flexibility, problem solving orientation and delivery within agreed timelines.



Fidelta announces an extension of its drug discovery service agreement with Heptares Therapeutics
Zagreb, Croatia, 5th September 2017 – Fidelta, a Galapagos company, is pleased to announce the continuation of an agreement with Heptares, whereby Fidelta will provide medicinal chemistry, DMPK and pharmacology services to advance Heptares' drug discovery …

Around the macrolide – Impact of 3D structure of macrocycles on lipophilicity and cellular accumulation
Maybe you would be interested to check our recently published article. It has been waiting for years to be published and we are happy it finally is! The article is available for free download for the next 6 weeks on


Your privacy is important to us.
© 2015 All Rights Reserved - Fidelta Ltd.